Assiut University Hospital - Women Health Hospital
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Assiut University
- Enrollment
- 64
- Primary Endpoint
- Clinical improvement of vaginitis.
Study Overview
Brief Summary
A previous study showed that in situ MTZ vaginal gel twice daily is more effective than the conventional vaginal gel product in sustained cure of BV( 4 weeks after treatment) (80.0% in the in-situ gel group as compared with 47.4 in the conventional gel group.The current study aims to compare the efficacy of the use of once daily in situ MTZ vaginal gel (0.8%) versus twice-daily conventional MTZ vaginal gel in treatment of BV.
Detailed Description
Bacterial vaginosis (BV) is one of the most frequently diagnosed infections in women attending genitourinary clinics. As 50% of cases of BV are asymptomatic, the true prevalence of this condition in the community is uncertain.Metronidazole (MTZ) is considered the drug of choice for the treatment of BV. It can be given either orally or locally. Formulations for the local administration of the drug include gels and suppositories.
The acceptance of suppositories is lower than the oral administration of the drug as they might cause irritation and thus affecting the patient's compliance. Moreover, the mode of administration of MTZ does not have a significant difference in the eradication of the pathogenic bacteria .
Among the metronidazole gels and lactic acid gels, for local application, lactic acid gels have been found to be more efficient and safer. The recurrence of BV is less common in patients treated with lactic acid gel when compared with patients treated with metronidazole gels. This may be attributed to the inhibition in the growth of the lactobacilli when MTZ is used for the treatment and depends on the concentration of the lactobacilli .
Intravaginal deliveries of MTZ for the treatment of BV have shown that there was an improvement in the clinical symptoms of the patients within 21-30 days of the starting of the treatment. Unfortunately, the vagina was not recolonized with lactobacilli within the stated period . The use of formulation consisting policarbophil-carbopol and lactic acid-chitosan mucoadhesive vaginal gels has also been reported and both of them have been found to be safe .
Cure rates following intravaginal treatment with MTZ account for 80-90% at the end of treatment and one month after the end of therapy. However, three months after the end of therapy the rate of relapses can overcome 30%. Persistence of an adherent bacterial biofilm, containing mostly Gardenerlla vaginalis is the main reason for failure of BV treatment .
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 20 Years to 40 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Women with proven diagnosis of bacterial vaginosis infection from the Outpatient Gynecological Clinic in Women Health Center Assiut University.
Exclusion Criteria
- •Women refusal to participate in the study.
- •Pregnant and nursing Women.
- •Anticipation of difficulty of subsequent communication with the woman.
Arms & Interventions
Group A received in situ MTZ vaginal gel
Received in situ MTZ vaginal gel once daily for 5 days. Treatment in this group was offered in the form of a bottle of an aqueous liquid (100 mL of a preparation composed of 0.8% MTZ, 20% pluronic F-127, 10% pluronic F-68, and 0.01% benzalkonium chloride). Women were asked to put 5 cc of the liquid into the vagina once daily for 5 days using a graded syringe and 10-cm long soft applicator.
Intervention: MTZ vaginal gel (Drug)
Group B received conventional MTZ vaginal gel
Group B (control group) received conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days, using the supplied nozzle, which applies about 5 gm of gel again in the same laying back position.
Intervention: Conventional MTZ vaginal gel (Drug)
Outcomes
Primary Outcomes
Clinical improvement of vaginitis.
Time Frame: 6 months
Therapeutic success will be defined as the presence of at least 3 signs of Amsel's criteria (Milky, homogeneous, adherent discharge; vaginal pH \> 4.5; release of fishy amine odor from vaginal fluid when mixed with 10% KOH (whiff test); and presence of \> 20 of clue cells).
Secondary Outcomes
No secondary outcomes reported
Investigators
Omar Mamdouh Shaaban
Women Health hospital
Assiut University